Teva Pham (TEVA) Said AZILECT Successfully Meet End Points
More News related to TEVA
- Teva Neuroscience Launches Spanish Parkinson's Disease Patient and Caregiver Web Site
- Unusual 11 Mid-Day Movers 9/26: IDEV, VSE, OSK, AEHR Higher; WM, NCC, SDA, WB Lower
- Indevus (IDEV) Announces Agreement With Teva (TEVA) to Develop Pagoclone for the Treatment of Stuttering
- Needham & Co Initiates Coverage on Drugs - Generic
- Stanford Starts Teva Pharmaceuticals (TEVA) at Buy
More News related to FDA
- Advanced Medical Optics (EYE) Granted FDA Premarket Approval of Healon D(R) Viscoelastic
- GTC Biotherapeutics (GTCB) Announces FDA Accepts ATryn(R) BLA Filing
- Genentech and OSI Phama Said Avastin/Tarceva Combo Fails As Second-Line Treatment For Lung Cancer
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today the successful completion of ADAGIO, the phase III study designed to demonstrate that AZILECT 1 mg tablets can slow down the progression of Parkinson's disease.
In the trial, the currently marketed AZILECT 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance. The study also confirmed the safety and tolerability of AZILECT.
Related Categories
FDAHot List
Stocks Mentioned
-0.58Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
